Arena Pharmaceuticals Inc., which advances small molecule drugs for varied therapeutic applications, recently announced an upcoming corporate update slated for 9 a.m. Jan. 12 at a California conference and planned for immediate online public availability.
The U.S. Senate implemented new protections on free speech Monday with the passage of H.R. 5111, 'The Consumer Review Fairness Act,' which prohibits gag clauses that could prevent truthful reviews of companies and services by consumers.
What unites all Parkinson’s disease (PD) patients is that no two people experience the disease in the same exact way, so industry practitioners have developed a resource network devoted to the community of affected individuals.
Five finalists for the $400,000 ALS Assistive Technology Challenge prize were recently announced in Washington, D.C., bringing the competition a step closer to its final phase when a single winner prevails Dec. 5 in Dublin.
Two providers of patient monitoring systems from different continents have forsaken their former competitiveness and united in a multi-year agreement to develop and streamline the latest advances in the field.
Responding to requests for administrative help with Parkinson’s patients, the Parkinson's Disease Foundation will sponsor an attorney-led webinar at 1 p.m. (EST) Tuesday, Nov. 8, for families, friends and care givers.
The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) recently released new recommendations for the dosing schedule of Trumenba (Meningococcal Group B) vaccinations.
Dr. Alan Schwartzstein, vice speaker of the American Academy of Family Physicians (AAFP) Congress of Delegates, recently released a blog post on the AAFP website describing the importance of combatting opioid addiction.
PatientPoint recently launched a new mobile app that will enable physicians to improve how they practice medicine, in addition to offering patients more information to benefit their overall experience.
Amgen has announced a phase-three study analyzing how XGEVA competes with zoledronic acid when it comes to meeting the primary endpoint of non-inferiority in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma.
Johnson & Johnson Innovation LLC (JJI) announced this week that it has created the Center for Device Innovation at Texas Medical Center as a collaboration between JJI and TMC to accelerate the development of medical devices.